

14th ESC Congress
4-7 May 2016, Basel

Adding DHEA to a contraceptive pill Androgen Restored Contraception


Yvette Zimmerman
Pantarhei Bioscience, The Netherlands



Disclosures

- Yvette Zimmerman is an employee of Pantarhei Bioscience, the company developing the clinical concept of Androgen Restored Contraception

Prevalence of contraceptive methods Overall rate in Western Europe: 72%*



*Percentage using contraception among women aged 20-45, married or in a union
**including prolonged abstinence, breastfeeding, douching, various folk methods and traditional methods not reported separately
Source: World contraceptive use 2011, United Nations

Effect contraceptive pill on sexual function and mood



- Effect of COC use on sexual function and mood is inconsistent, both positive and negative¹
- Diminished sexual function and mood disturbances have been reported as side effect of COCs²
- Studies have also been investigating the effects of COCs on side effects in relation to androgen levels; these studies report conflicting results³

¹ Kahn & Halbreich (2001); Davis & Castaño (2004); Burrows et al. (2012); Poroma & Segeblath (2012); Pastor et al. (2013)
² Sanders et al. (2001); Moreau et al. (2007); Wakiemier et al. (2010); Elaut et al. (2012); Gignat et al. (2013); Smith et al. (2004)
³ Bancroft et al. (1991); Graham et al. (1995); Graham et al. (2007); Genco et al. (2007); Shufali et al. (2010); Schaffr et al. (2010); Caruso et al. (2011); Battaglia et al. (2012); Elaut et al. (2012); Battaglia et al. (2014)

Effect of combined oral contraceptives on testosterone and SHBG

- Systematic review & meta-analysis
- 42 studies; n=1,495 healthy young women
- Significant ($P < 0.0001$) decrease T levels:
 - Total T: ↓31%
 - Free T: ↓61%
 - No differences between various COC types
 - No relationship with SHBG increase (which ranged from 50-250%)
- Significant ($P < 0.0001$) increase SHBG levels:
 - Dose-dependent estrogen (EE) effect
 - Differently antagonised depending on the androgenicity of the progestin



Zimmerman et al. Hum Reprod Update (2014) 20:76-105

Does it matter? Yes or No

- Symptoms female androgen insufficiency¹:
 - Diminished sexual function
 - Reduced well-being and quality of life (mood, affect, energy)
 - Negative effects on bone and muscle mass
- Endocrine society recommends against making a diagnosis and treatment²
 - Lack of well-defined clinical syndrome of androgen insufficiency
 - Absence of normative data of total and free T levels
 - Lack of long-term safety data

¹ Bachmann et al. Fertil Steril (2002); 2. Wieman et al. JCEM (2006)

Difficulties investigating effects androgen deficiency on sexual function and mood

- Effects of androgens on sexuality are too subtle to measure with questionnaires like the FSFI measuring "dysfunctions"
- There are large inter-individual differences in the effects of androgens on sexual processing
- Some women are more sensitive to changes in T than others¹
- Linking levels of endogenous sex steroids with sexual functioning is difficult due to individual variability in biosynthesis, enzymatic intracrine conversion, receptor binding, absorption rate, bioavailability, elimination, etc.

¹Bancroft & Gaham. *Hormones Behavior* (2011); 59:717-729

Androgen Restored Contraception (ARC)

- The ARC concept refers to a combined oral contraceptive (COC) containing dehydroepiandrosterone (DHEA) with the objective to preserve sexual function by maintaining normal androgen levels, in particular free testosterone
- Why DHEA?
 - DHEA is a natural precursor hormone for androgens
 - Oral DHEA is metabolised to T and increases T levels dose dependently¹
 - 50 mg DHEA increases T by about 1 nmol/L, is safe and does not increase estradiol¹
 - Allows oral-only product

¹Legrain, Baulieu et al. *JEM* (2000)



Two large prospective, randomised, double-blind, placebo-controlled studies



ARC-AMC study van Lunsen and Laan, Amsterdam, NL

- Participants: 81 healthy COC users (20-35 yrs) and in steady relationship
- Treatment (cross-over design):
 - One (1) month no hormonal contraception
 - Two COCs investigated both 30 µg EE and either 150 µg levonorgestrel (LNG) or 3 mg DRSP
 - Five (5) cycles with placebo followed by 5 cycles with 50mg DHEA or the reverse


ARC-AMUSA study Foidart and Pintiaux, Liège, B

- Participants: 99 healthy and new COC users (18-35 yrs)
- Treatment
 - Three (3) months no hormonal contraception
 - Three (3) cycles 30 µg EE/3 mg drospirenone (DRSP)
 - Six (6) cycles EE/DRSP with 50mg DHEA or placebo

Study objective

To investigate the endocrine and clinical effects of the pill with and without co-administration of DHEA.


Significant change ($P < 0.05$) in total T, SHBG and free T after use of 3-5 cycles of a COC containing 30 µg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 µg EE and 150 µg levonorgestrel (LNG)



Zimmerman et al. *ESHRE* (2014)

Free T levels during the normal menstrual cycle and COC use


1. Huge variation of free T levels during the normal menstrual cycle
2. COC reduces free T significantly and in all 99 women



Zimmerman et al. *ESHRE* (2014)

Effect adding DHEA/placebo to COC on total T, SHBG and free T

* Significant difference between baseline and after 5 cycles with DHEA or placebo ($P < 0.05$)



Outcome measures for clinical effects

➤ ARC-AMUSA study:

- Questionnaires: McCoy Female Sexuality Questionnaire (MFSQ), Moos Menstrual Distress Questionnaire (MDQ), Quality of Life (Q-LES-Q)

➤ ARC-AMC study:

- Questionnaires: FSFI, FSFS-R
- SexLab: genital sexual arousal (VPA) & subjective sexual arousal (SSAQ)
- At home setting with Sexual Function Diary (SFD; 1 week prior to SexLab):
 - self-reported sexual arousal and desire
 - frequency of sexual activities per week
 - sexual response to these activities




Women taking an EE/LNG and EE/DRSP COC reported a significant decline in sexual function

- FSFI:
 - Three FSFI domains indicated worse sexual function with EE/LNG use compared to baseline ($P < 0.05$)
 - Lower FSFI scores during COC use with 33.3% of women below the cut-off dysfunctional FSFI score of 26.55 compared to 24.4% of women not using COC
- SFD (diary): Significant worsening of sexual desire and arousability ($P < 0.05$) after 5 cycles COC; no difference found between LNG or DRSP
- SFDS-R: No difference
- Laboratory setting: No differences in genital response to erotic fantasy and film)
- MFSQ: Significant worsening for global score, sexual interest and orgasm ($P < 0.001$)

Zimmerman et al. Contraception (2015); Van Lunsen et al. (2016; submitted)

Effect adding DHEA/placebo to COC on frequency of sexual activity


* Significant reduction to sexual initiatives of the partner with DHEA compared to placebo



Van Lunsen et al. (2016; submitted)

Receptiveness to sexual encounters initiated by partner was higher when women were taking COC with DHEA compared to COC with placebo

Effect adding DHEA/placebo to COC on levels of sexual desire and arousability measured by SFD (diary)



Van Lunsen et al. (2016; submitted)

Sexual arousability, desire and fantasies significantly higher in women with highest levels of free testosterone with DHEA compared to placebo * $P < 0.02$

In this group (Q4): 14 women were using EE/LNG/DHEA and 4 women EE/DRSP/DHEA

Conclusions

- COCs significantly suppress androgen concentrations, especially free T (decrease of 68-86%)
- COC use has unfavourable effects on sexual function
- Addition of 50 mg DHEA restores total and free testosterone when combined with an LNG pill, but this dose is too low for a DRSP pill
- Maintenance of androgen levels by adding DHEA to a COC preserves sexual arousability and desire, particularly in those women with a strong free T response to DHEA
- Co-treatment with DHEA for 5 cycles was safe and did not cause symptoms of hyperandrogenicity (except for a few single cases, both during DHEA and placebo)

Acknowledgements



Thank you for your attention